Brumlik Michael J, Daniel Benjamin J, Waehler Reinhard, Curiel David T, Giles Francis J, Curiel Tyler J
University of Texas Health Sciences Center at San Antonio, San Antonio Cancer Institute, 2040 Babcock Road, Suite 201, San Antonio, TX 78229, USA.
Expert Opin Drug Deliv. 2008 Jan;5(1):87-103. doi: 10.1517/17425247.5.1.87.
Many agents used to treat cancer are toxic to normal tissues. Thus, treatments delivering drug specifically to tumour, while minimising exposure to normal tissue, may be advantageous over non-targeted treatments. The exquisite specificity of the immune system has been used successfully to help develop targeted anticancer agents. The most common (and successful) tissue-specific targeting strategies rely on antibody conjugates, but additional approaches, including targeting through cytokines, peptides and recombinant viruses, have also been used successfully. This review summarises the agents exploiting the immunological principles of target specificity to help maximise delivery to tumour while minimising collateral damage to normal tissues. Such targeted molecules are collectively referred to as immunoconjugates.
许多用于治疗癌症的药物对正常组织有毒性。因此，将药物特异性递送至肿瘤，同时尽量减少对正常组织的暴露，这种治疗方法可能比非靶向治疗更具优势。免疫系统的高度特异性已被成功用于帮助开发靶向抗癌药物。最常见（且成功）的组织特异性靶向策略依赖于抗体偶联物，但其他方法，包括通过细胞因子、肽和重组病毒进行靶向，也已成功应用。本综述总结了利用靶标特异性免疫学原理的药物，以帮助在最大程度将药物递送至肿瘤的同时，将对正常组织的附带损害降至最低。此类靶向分子统称为免疫偶联物。
